Paper7909557
Xanomeline: a novel muscarinic receptor agonist with functional selectivity for M1 receptors.
Shannon HE and 12 others. J Pharmacol Exp Ther, 1994. Cited by 149 papers, by iCite.
Cite this record
ConductScience Library. Xanomeline: a novel muscarinic receptor agonist with functional selectivity for M1 receptors. Papers, record 7909557. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/7909557
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Xanomeline: a novel muscarinic receptor agonist with functional selectivity for M1 receptors.
- PubMed
Topics33
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Parasympathomimetics | Major topic |
| Pyridines | Major topic |
| Receptors, Muscarinic | Major topic |
| Thiadiazoles | Major topic |
| Animals | |
| Body Temperature | |
| CHO Cells | |
| Cricetinae | |
| Depression, Chemical | |
| Gastrointestinal Motility | |
| Guinea Pigs | |
| Heart Atria | |
| Heart Rate | |
| Humans | |
| Hydrolysis | |
| Ileum | |
| In Vitro Techniques | |
| Inositol Phosphates | |
| Male | |
| Muscle Contraction | |
| Muscle, Smooth | |
| Myocardial Contraction | |
| Neurotransmitter Agents | |
| Rabbits | |
| Radioligand Assay | |
| Rats | |
| Rats, Sprague-Dawley | |
| Receptors, Neurotransmitter | |
| Salivation | |
| Transfection | |
| Tremor | |
| Urinary Bladder | |
| Vas Deferens |
Source PubMed
Cited by50
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 149 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42556870 | Altered Functional Connectivity in the Reward Circuit in Betel Quid-Dependent Chewers. | Addict Biol | 2026 | https://conductscience.org/library/papers/42556870 | PubMed |
| 42450007 | Xanomeline-Trospium Validates Muscarinic Agonism as an Effective Non-Dopaminergic Treatment for Schizophrenia. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42450007 | PubMed |
| 41633901 | Targeting muscarinic receptors for treating schizophrenia. | Neurotherapeutics | 2026 | https://conductscience.org/library/papers/41633901 | PubMed |
| 41343242 | Protein-protein interaction-interfering peptide rescues dysregulated NMDA receptor signaling. | JCI Insight | 2026 | https://conductscience.org/library/papers/41343242 | PubMed |
| 41147362 | Targeting disrupted networks in schizophrenia: Can muscarinic drugs make a fundamental difference? | J Psychopharmacol | 2025 | https://conductscience.org/library/papers/41147362 | PubMed |
| 41052274 | Antipsychotic drugs at 75: the past, present, and future of psychosis management. | Br Med Bull | 2025 | https://conductscience.org/library/papers/41052274 | PubMed |
| 40574777 | Targeting muscarinic receptors in schizophrenia treatment: Novel antipsychotic xanomeline/trospium chloride. | World J Psychiatry | 2025 | https://conductscience.org/library/papers/40574777 | PubMed |
| 40165106 | Does KarXT (xanomeline-trospium) represent a novel approach to schizophrenia management? A GRADE-assessed systematic review and meta-analysis of randomized controlled clinical trials. | BMC Psychiatry | 2025 | https://conductscience.org/library/papers/40165106 | PubMed |
| 39871564 | Advancements in Managing Schizophrenia through Classical Approaches, Mechanisms, and Deep Brain Stimulation. | Curr Pharm Des | 2025 | https://conductscience.org/library/papers/39871564 | PubMed |
| 39857669 | Overview of Novel Antipsychotic Drugs: State of the Art, New Mechanisms, and Clinical Aspects of Promising Compounds. | Biomedicines | 2025 | https://conductscience.org/library/papers/39857669 | PubMed |
| 39143241 | A golden age of muscarinic acetylcholine receptor modulation in neurological diseases. | Nat Rev Drug Discov | 2024 | https://conductscience.org/library/papers/39143241 | PubMed |
| 38904739 | Current Findings and Potential Mechanisms of KarXT (Xanomeline-Trospium) in Schizophrenia Treatment. | Clin Drug Investig | 2024 | https://conductscience.org/library/papers/38904739 | PubMed |
| 38839931 | Normative modelling of molecular-based functional circuits captures clinical heterogeneity transdiagnostically in psychiatric patients. | Commun Biol | 2024 | https://conductscience.org/library/papers/38839931 | PubMed |
| 38317082 | M1 cholinergic signaling in the brain modulates cytokine levels and splenic cell sub-phenotypes following cecal ligation and puncture. | Mol Med | 2024 | https://conductscience.org/library/papers/38317082 | PubMed |
| 37835460 | Selective Activation of M1 Muscarinic Receptors Attenuates Human Colon Cancer Cell Proliferation. | Cancers (Basel) | 2023 | https://conductscience.org/library/papers/37835460 | PubMed |
| 37193547 | Xanomeline-Trospium and Muscarinic Involvement in Schizophrenia. | Neuropsychiatr Dis Treat | 2023 | https://conductscience.org/library/papers/37193547 | PubMed |
| 36983018 | Canonical and Non-Canonical Antipsychotics' Dopamine-Related Mechanisms of Present and Next Generation Molecules: A Systematic Review on Translational Highlights for Treatment Response and Treatment-Resistant Schizophrenia. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/36983018 | PubMed |
| 36973270 | Cross-diagnostic determinants of cognitive functioning: the muscarinic cholinergic receptor as a model system. | Transl Psychiatry | 2023 | https://conductscience.org/library/papers/36973270 | PubMed |
| 36782010 | Structural basis of efficacy-driven ligand selectivity at GPCRs. | Nat Chem Biol | 2023 | https://conductscience.org/library/papers/36782010 | PubMed |
| 36414626 | Effectiveness of KarXT (xanomeline-trospium) for cognitive impairment in schizophrenia: post hoc analyses from a randomised, double-blind, placebo-controlled phase 2 study. | Transl Psychiatry | 2022 | https://conductscience.org/library/papers/36414626 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/7909557
GET https://conductscience.org/api/papers/v1/7909557/cited_by?page=2